Fidji Simo on her life after OpenAI and new startup, ChronicleBio
Fortune 5
Fidji Simo left her role as an OpenAI executive in early July and launched the startup ChronicleBio to work on chronic disease research using AI. ChronicleBio will use AI to analyze blood to break POTS patients into more granular cohorts. That approach is meant to make clinical drug trials more targeted and less likely to come out inconclusive by linking symptoms to underlying causes rather than treating patients as one group.